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1. Introduction
 Ankylosing spondylitis (AS) is a chronic inflammatory 
disease at peripheral joints, sacroiliac joints and insertion 
of tendons, which is commonly seen in adolescent males. 
90% of patients with AS are HLA-B27 positive. In China, 
the prevalence of ankylosing spondylitis is about 0.3%, with 
its main manifestations in the early stage including lesions 
at insertion sites of the ligament and synovitis. Spinal 
ankylosis caused by ligament calcification may occur at late 
stage, which may lead to disability, seriously influencing the 
patient’s quality of life. However, up till now, the etiology 
of AS is still not clear. It may be related to environmental 
factors, genetic susceptibility factors, infection, disorders of 
the immune system and other factors[1,2].
2. Materials and methods
2.1. General information
  Between January 2009 and January 2012, 48 active AS 
patients in our hospital were selected in our study. All 
patients are diagnosed based on the modified New York 
criteria of 1984[3]. There were 45 male and 3 female with a 
mean age of (34.5依10.6) years (range, 17-61 years). The mean 
duration of illness was 6.8 months (range, 0.5-27 months) 
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with HLA-B27 positive in 42 cases and HLA-B27 negative 
in 6 cases. Patients were excluded if they had a history 
taking methotrexate and other drug use history. Those who 
had infection and other connective tissue diseases were also 
excluded. In addition, 40 healthy subjects were selected from 
our hospital employees as a control group. All the patients 
in the control group had no history of chronic low back pain 
or joint disease. Systemic infection and connective tissue 
disease were also excluded.
2.2. Treatment and detection index
 
  All active AS patients were given nonsteroidal anti-
inflammatory drugs and drugs of chronic effects such as 
methotrexate and sulfasalazine. A detailed and thorough 
examination was given to the selected objects. Bath 
ankylosing spondylitis disease activity index (BASDAI), 
Bath ankylosing spondylitis functional index (BASFI) and 
Bath ankylosing spondylitis metrology index (BASMI) were 
measured before treatment, 12 weeks and 24 weeks after 
treatment, respectively. Meanwhile, blood samples were 
drawn at eight in the morning during fasting conditions for 
measuring CRP, ESR, blood routine examination, hepatic 
and renal function. Fasting blood samples of all subjects 
were taken at 8 in the morning, which were collected 
and stored at -30℃ and serum IL-2, IL-11 levels were 
measured using double antibody sandwich enzyme linked 
immunosorbent assay.
2.3. Statistical analysis  
  Statistical analysis was performed using SPSS16.0 software. 
Data were expressed as mean 依 standard deviation. 
Statistical comparisons were by t test and correlation 
analysis. It was considered statistically significant if the P 
value was less than 0.05.
3. Results
3.1. Comparison of curative effect before and after treatment 
in patients with AS
 The curative effect before and after treatment in patients 
with AS showed that the BASDAI score, BASFI score and 
BASMI score of the AS patients 12 weeks and 24 weeks after 
treatment significantly decreased compared with those 
before treatment (P<0.05), which indicated the effectiveness 
of the treatment(Table 1). 
Table 1
Curative effect before and after treatment in patients with 
AS.  
Period BASDAI BASFI BASMI
Before  treatment 3.4依2.0 2.8依1.8 3.4依2.1
12 weeks after treatment 2.4依1.7* 2.2依1.5* 2.7依1.4*
24 weeks after treatment 1.7依1.2* 1.6依1.3* 1.7依1.2*
*:  P<0.05, compared with before treatment.
3.2. ESR and CRP levels before and after treatment in 
patients with AS
  ESR and CRP levels before and after treatment in patients 
with AS showed that ESR and CRP levels of the AS patients 
12 weeks and 24 weeks after treatment significantly 
decreased compared with those before treatment (P<0.05)
(Table 2). 
Table 2
Comparison of ESR and CRP levels before and after treatment in 
patients with AS.
Period ESR(mm/h) CRP(mg/L)
Before  treatment 34.6依9.8 28.1依6.9
12 weeks after treatment 26.2依8.7* 17.2依5.3*
24 weeks after treatment 21.1依6.8* 12.4依4.1*
 *:  P < 0.05, compared with before treatment.
3.3.Expression of serum IL-2 and IL-11  
  Significant difference was noted for serum IL-2 and IL-11 
levels between 12 weeks and 24 weeks after treatment and 
before treatment (P<0.05). And no statistically significance 
was observed for serum IL-2 and IL-11 levels between 
normal control group and those of patients in AS group 24 
weeks after treatment (P>0.05) (Table 3).
3.4. Correlation detection 
  Pearson’s linear-correlation analysis showed that serum 
IL-2 level had a positive correlation with BASDAI, BASFI, 
BASMI, ESR and CRP (r=0.661, 0.547, 0.474, 0.362, 0.416, 
P<0.05) and serum IL-11 level had a negative correlation 
with BASDAI, BASFI, BASMI, ESR and CRP(r=-0.629, -0.412, 
-0.422, -0.387, -0.408, -0.315, P<0.05).
4. Discussion
  AS is a chronic inflammatory disease which involves 
Table 3
Expression of serum IL-2 and IL-11. 
Group IL-2(pg/L) IL-11(pg/L)
AS group Before  treatment 156.3依48.9 116.2依37.6
12 weeks after treatment 101.2依35.3 146.5依39.2
24 weeks after treatment   64.8依11.2 168.3依41.4
Normal control group   56.6依8.9 178.7依45.7
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the spine and the peripheral joints to different extent. 
The incidence of AS is closely related to HLA-B27. It is 
commonly seen in China with a high incidence ranging in 
age from 10 to 30 years[4]. No obvious symptoms or signs 
were noted in the early stages of AS. Its early onset may 
be associated with abnormal bone metabolism, enhanced 
bone resorption and relative lack of bone formation. With 
the development of lesions, rigid peripheral joints and the 
spine may occur, which will lead to deformity or disability. 
Traditional therapies include nonsteroidal anti-inflammatory 
drugs or adrenal cortical hormones, but they can only 
alleviate the symptoms but cannot improve symptoms[5,6]. 
In our study, drugs such as methotrexate and sulfasalazine 
were used to treat the patients and the results showed that 
the BASDAI score, BASFI score and BASMI score of the AS 
patients 12 weeks and 24 weeks after treatment significantly 
decreased compared with those before treatment (P<0.05). 
It showed that methotrexate and sulfasalazine could largely 
achieve a therapeutic purpose for AS patients. 
  Recently, cytokine mediated effects attract more and more 
attention. IL-2 is one of the most important lymphokines 
ever known in the occurrence and development of joint 
disease with a molecular mass of 15 kD, which is produced 
by mitogen, antigen or T cells activated by T cell antigen 
receptor monoclonal antibody[7]. Almost all activated T 
cells can secrete IL-2, among which helper T cells account 
for 80%. Therefore, IL-2 expression mainly reflects TH 
function. IL-2 can maintain long-term growth potential
in vitro, activate T cells, NK cells and promote the functional 
expression and proliferation of B-cells. Therefore, IL-2 
plays an important regulatory role in humoral and cell-
mediated immunity.
  The results of this study showed that the expression of 
IL-2 in AS patients was significantly higher than that in 
the normal group, which indicated that there might be 
an abnormal increase in activated immune cells in the 
peripheral blood in AS patients. 
  Increased IL-2 secretion reflected the increased exogenous 
activation on the body and the enhanced TH function. In 
addition, the results showed that the serum IL-2 level 
had a positive correlation with BASDAI, BASFI, BASMI, 
ESR and CRP. After treatment, the IL-2 levels gradually 
decreased, indicating that the IL-2 level could reflect the 
disease activity of AS, which played an important role in the 
pathogenesis of AS.
  IL-11 belongs to IL-6 cytokine family, secreted by cells of 
stromal cell lines, which is a multifunctional cytokine[8,9]. 
The local IL-11 in bone is secreted by osteoblasts, which 
also plays an important role on osteoclasts, however. On 
one hand, it can inhibit the activity of osteoblasts and 
inhibit bone formation. On the other hand, it can stimulate 
proliferation of osteoclasts and thereby promote bone 
resorption. Recent studies have shown that, some systemic 
or local factors can produce IL-11 by stimulating osteoblasts 
to influence osteoblasts and osteoclasts, regulating bone 
metabolism. The study of Shinohara et al[10] showed that 
in the presence of IL-11, osteoclasts had the function of 
bone resorption, indicating that IL-11 was an important 
regulatory factor in both physiological and pathological 
conditions for regulation of bone mineral density. Our study 
showed that the serum level of IL-11 in AS patients was 
lower than that in normal control group. The possible reason 
was that the local or systemic inflammation inhibited the 
activity of osteoblasts, so as to reduce the secretion of IL-
11. In addition, inflammation also stimulated osteoclasts to 
enhance their activity and bone resorption, thus played a 
role in the negative feedback regulation of IL-11 production, 
which reduced the IL-11 production. The reduction of IL-
11 caused a decrease in the inhibition of osteoblast. The 
overexpression of osteoblast finally led to local osteophyte 
formation. But this study showed that serum IL-11 level had 
a negative correlation with BASDAI, BASFI, BASMI, ESR and 
CRP. After treatment serum IL-11 level gradually started 
to rise, showing that serum IL-11 in AS patients correlated 
negatively with the degree of AS and correlated closely with 
the onset of AS.
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